UCB : FDA Defers Action On BLA For Bimekizumab Due To Travel Restrictions
16/10 19:35
(RTTNews) - UCB said that the U.S. Food and Drug Administration has informed the company that it was unable to complete review of the Biologics License Application or BLA for bimekizumab for the treatment of moderate to severe plaque psoriasis by the Prescription Drug User Fee Ac...